Benedetta Chiodini

Dr. Benedetta Chiodini

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2017 in Transplant International
Verified
Journal Article
Open access
PDF file
BCBenedetta Chiodini
Benedetta Chiodini
JHJean Herman
Jean Herman
KLKsenija Lolin
Ksenija Lolin
BABrigitte Adams
Brigitte Adams
EHElise Hennaut
Elise Hennaut
KIKhalid Ismaili
Khalid Ismaili
Kidney transplantation (KT) is often delayed in small children because of fear of postoperative complications. We report early- and long-term outcomes in children transplanted at ≤15 kg in the two largest Belgian pediatric transplant centers. Outcomes before (period 1) and since the introduction of basiliximab and mycophenolate-mofetil in 2000 (period 2) were compared. Seventy-two KTs were realized between 1978 and 2016: 38 in period 1 and 34 in period 2. Organs came from deceased donors in 48 (67%) cases. Surgical complications occurred in 25 KTs (35%) with no significant difference between the two periods. At least one acute rejection (AR) occurred in 24 (33%) KTs with significantly less patients experiencing AR during period 2: 53% and 12% in period 1 and, period 2 respectively (P < 0.001). Graft survival free of AR improved significantly in period 2 compared with period 1: 97% vs. 50% at 1 year; 87% vs. 50% at 10 years post-KT (P = 0.003). Graft survival tended to increase over time (period 1: 74% and 63% at 1 and 5 years; period 2: 94% and 86% at 1 and 5 years; P = 0.07), as well as patient survival. Kidney transplantation in children ≤15 kg remains a challenging procedure with 35% of surgical complications. However, outcomes improved and are nowadays excellent in terms of prevention of AR, patient and graft survival.

16 March 2017 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
KLKsenija Lolin
Ksenija Lolin
BCBenedetta Chiodini
Benedetta Chiodini
EHElise Hennaut
Elise Hennaut
BABrigitte Adams
Brigitte Adams
KDKarin Dahan
Karin Dahan
KIKhalid Ismaili
Khalid Ismaili
We present a rare early presentation of a ADCK4-related glomerulopathy. This case is of interest as potentially treatable if genetic results are timely obtained. We report the case of a 5-year-old boy who was identified with significant proteinuria by a urinary routine screening program for school children. Physical examination revealed dysplastic ears and abnormal folded pinna. Albumin level was 41 g/L (39–53 g/L), and urine proteins/creatinine ratio was 2.6 g/g. Renal ultrasound showed enlarged kidneys and perimedullary hyperechogenicity. Treatment by angiotensin-converting-enzyme inhibitor was not beneficial. Renal biopsy showed signs of focal segmental glomerulosclerosis. After 4 years of follow-up, he developed a clinical nephrotic syndrome and no response to prednisone and other immunosuppressive agents was obtained. Within 6 months, he was in end-stage-renal-failure (ESRF) and hemodialysis was started. He was transplanted at 10 years with his mother’s kidney. Genes known to be responsible in steroid-resistant nephrotic syndromes were tested. Our patient is compound heterozygous for two mutations in the aarF domain-containing-kinase 4 (ADCK4) gene. ADCK4 gene is one of the genes involved in coenzyme Q10 (CoQ10) biosynthesis, is located in chromosome 19q13.2 and expressed in podocytes. ADCK4 mutations show a largely renal-limited phenotype. The nephropathy usually presents during adolescence, fast evolves towards ESRF, and may be treatable by CoQ10 supplementation if started early in the disease. Our patient presented nephrotic range proteinuria at 5 years, and he reached ESRF at 10 years. ADCK4-related glomerulopathy is an important novel and potentially treatable cause of isolated nephropathy not only in adolescents, but also in children in their first decade of life. Discovery of important proteinuria in an asymptomatic child should prompt early genetic investigations.

17 August 2022 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
BCBenedetta Chiodini
Benedetta Chiodini
ABAnita Sofia Bellotti
Anita Sofia Bellotti
WMWilliam Morello
William Morello
CBChiara Bulgaro
Chiara Bulgaro
IFIlaria Farella
Ilaria Farella
KWKarl Martin Wissing
Karl Martin Wissing

15 May 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
BCBenedetta Chiodini
Benedetta Chiodini
PGPauline Guillaume-Gentil
Pauline Guillaume-Gentil
CVCharlotte Vanhomwegen
Charlotte Vanhomwegen
EHELISE HENNAUT
ELISE HENNAUT
KLKsenija Lolin
Ksenija Lolin
KIKhalid Ismaïli
Khalid Ismaïli
BK polyomavirus (BKPyV) is still a real threat in the management of kidney transplantation. Immunosuppressive treatment disrupts the equilibrium between virus replication and immune response, and uncontrolled BKPyV replication leads to nephropathy (BKPyV nephropathy). The first evidence of BKPyV reactivation in transplant recipients is the detection of viral shedding in urine, which appears in 20% to 60% of patients, followed by BKPyV viremia in 10–20% of kidney transplant recipients. BKPyV nephropathy eventually occurs in 1–10% of this population, mainly within the first 2 years post-transplantation, causing graft loss in about half of those patients. Few data exist regarding the pediatric population and we focus on them. In this paper, we review the existing diagnostic methods and summarize the evidence on the role of BKPyV humoral and cellular immunity in modulating the clinical course of BKPyV infection and as potential predictors of the outcome. We look at the known risk factors for BKPyV nephropathy in the immunosuppressed patient. Finally, we propose a sensible clinical attitude in order to screen and manage BKPyV infection in kidney transplant children.

8 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
BCBenedetta Chiodini
Benedetta Chiodini
GPGuillaume-Gentil Pauline
Guillaume-Gentil Pauline
CVCharlotte Vanhomwegen
Charlotte Vanhomwegen
EHELISE HENNAUT
ELISE HENNAUT
KLKsenija Lolin
Ksenija Lolin
KIKhalid Ismaïli
Khalid Ismaïli
BK polyomavirus (BKPyV) is still a real threat in the management of kidney transplantation. Immunosuppressive treatment disrupts the equilibrium between virus replication and immune response, and uncontrolled BKPyV replication leads to nephropathy (BKPyV nephropathy). The first evidence of BKPyV reactivation in transplant recipients is the detection of viral shedding in urine, which appears in 20% to 60% of patients, followed by BKPyV viremia in 10-20% of kidney transplant recipients. BKPyV nephropathy eventually occurs in 1-10% of this population, mainly within the first 2 years post-transplantation, causing graft loss in about half of those patients. Few data exist regarding the pediatric population and we focus on them. In this paper, we review the existing diagnostic methods, we summarize the evidences on the role of BKPyV humoral and cellular immunity in the modulation of the clinical course of BKPyV infection and as potential predictors of the outcome. We look at the known risk factors of BKPyV nephropathy in the immunosuppressed patient. Finally, we propose a sensible clinical attitude in order to screen and manage BKPyV infection in kidney transplant children.

27 May 2026 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
EHElise Hennaut
Elise Hennaut
NGNatacha Gubbelmans
Natacha Gubbelmans
DMDelphine Martiny
Delphine Martiny
KLKsenija Lolin
Ksenija Lolin
PGPauline Guillaume-Gentil
Pauline Guillaume-Gentil
KIKhalid Ismaili
Khalid Ismaili